PDF VersionNew York, NY and Tampa, FL – January 5, 2026 – Nouveau Biosciences, a biotechnology company pioneering nanomedicines and targeted drug delivery to improve cancer therapeutics, and CanceRx, a purpose-driven funding and development platform focused on advancing innovative oncology treatments through long-duration capital and strategic partnerships, today announced that the two organizations have entered into a Letter of Intent (LOI).
The LOI outlines the intent of Nouveau Biosciences and CanceRx to collaborate on the clinical advancement and regulatory development of NBS-002, Nouveau’s second pipeline asset built on the company’s proprietary technology. The collaboration is intended to support the progression of NBS-002 toward regulatory submission and eventual commercialization through a strategic licensing pathway.
CanceRx employs a differentiated development model that emphasizes long-horizon capital and active partnership to advance promising oncology assets through key clinical and regulatory milestones. This approach is designed to align with pharmaceutical industry preferences for acquiring well-validated, de-risked programs for late-stage development and market launch.
“We are excited to enter into this Letter of Intent with CanceRx as we advance NBS-002 into the next phase of development,” said Owen A. O’Connor, M.D., Ph.D., Founder, Chief Executive Officer, and Chairman of Nouveau Biosciences. “CanceRx’s mission-driven model, focused on scientific rigor, patient impact, and long-term value creation, aligns closely with our strategy for building a sustainable and differentiated oncology pipeline. This LOI represents an important step in bringing our innovative new drugs to the patients who need them most.”
Nouveau Biosciences has developed a proprietary polymer-based nanoparticle platform designed to enhance drug tolerability, targeting, and therapeutic performance. The technology enables the encapsulation and delivery of a wide range of anti-cancer agents, including rational combinations. NBS-002 builds on this validated chemistry and biology, reinforcing the company’s ability to generate a pipeline of IP-protected, clinically relevant nanotherapeutic drug candidates.
“Nouveau Biosciences represents the type of innovative oncology company we seek to support,” said Clifford S. Gibbons, JD, Executive Director of CanceRx Foundation, Inc. and Managing Director of CanceRx, LLC. “Their drug discovery and nanomedicine capabilities, including NBS-002, have the potential to improve how cancer therapies are developed and delivered. We look forward to working together to advance this program for patients.”
Further details regarding the proposed collaboration will be announced upon the execution of definitive agreements.
About Nouveau Biosciences
Nouveau Biosciences is an innovative biotechnology company that deploys a proprietary platform technology, the Nouveau Nexus™, that integrates the latest scientific advances in cancer biology, genomics, computational biology and nanomedicine to produce precision targeted drugs tailored for very specific types of cancer. Its polymer-based nanoparticles are engineered to deliver both individual drugs and optimized combinations with enhanced precision, leading to improved tolerability and efficacy. The company’s lead programs are clinic-ready, backed by strong intellectual property, and designed to address high-need oncology indications. The technology represents a quantum advance in the generation of highly precision targeted drugs, offering innumerable advances over technologies.
About CanceRx
CanceRx is a nonprofit and investment platform designed to support the development of promising cancer drugs through long-duration funding, clinical guidance, and FDA submission support. The organization partners with scientific innovators to bring life-changing oncology therapies to patients, and works closely with pharmaceutical companies to license and scale validated assets. Learn more at https://cancerx.us.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the companies’ future plans, development and licensing of cancer therapeutics, and the potential success of the collaboration. All statements other than statements of historical fact are forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements. Nouveau Biosciences undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by law.
Media Contact
Petrina Whyte
media@nouveaubiosciences.com